Phase IIIb randomized study of lenalidomide plus rituximab (R-2) followed by maintenance in relapsed/refractory NHL: Analysis of patients with double-refractory or early relapsed follicular lymphoma (FL).-MedSci.cn

Phase IIIb randomized study of lenalidomide plus rituximab (R-2) followed by maintenance in relapsed/refractory NHL: Analysis of patients with double-refractory or early relapsed follicular lymphoma (FL).

Andorsky, DJ; Yacoub, A; Melear, JM; Coleman, M; Kolibaba, KS; Brooks, HD; Bitran, JD; Fanning, SR; Lansigan, F; Ricker, JL; Foon, KA; Liu, DF; Llorente, M; Li, JH; Sharman, JP

JOURNAL OF CLINICAL ONCOLOGY, 2017; 35 ( ):

科室
- - 订阅+
  - 更多科室
工具
服务